At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
In Brief
A clinical study evaluating Blood sampling - healthy volunteers, Blood sampling - sickle cell patients arm - stable condition, and 2 other interventions for Sickle Cell Disease. Completed, enrolled 64 participants across 1 site.
Detailed Summary
Sickle cell disease is a genetic disorder caused by a point mutation on the amino acid sequence of the β chain of hemoglobin. The most expressive and most frequent complication of the disease is vaso-occlusive crisis, dominated by a painful syndrome. In addition to vaso-occlusive crises, many more chronic biological disturbances are observed in sickle cell patients.Sickle cell disease is considered nowadays as a hypercoagulable state. However, the approach used so far to the measure of clotting in sickle cell disease was segmented in the sense that the various components of the hemostatic balance were studied separately.The thrombin generation test is a functional test which explores the coagulation globally, integrating both pro players that anticoagulants actors in the system. The investigators already used this test to demonstrate that the hemostatic potential was high in a cohort of affected children compared to control children of the same age. This test will be used to characterize the hemostatic potential of adult sickle cell patients followed at the CHU Brugmann Hospital.
Study Details
Timeline
Interventions
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.